JW (Cayman) Therapeutics Co (HKSE:02126) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02126 JW (Cayman) Therapeutics Co Ltd HKSE:02126
45 GF Score
Price HK$1.61
GF Value HK$4.08
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02126
45GF Score
JW (Cayman) Therapeutics Co Ltd HKSE:02126
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JW (Cayman) Therapeutics Co (HKSE:02126) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of HK$1.61 is trading 60.5% below its estimated GF Value™ of HK$4.08. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for HKSE:02126:

  • FFO:
  • GF Value™: HK$4.08 vs. price of HK$1.61 (60.5% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the HKSE:02126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JW (Cayman) Therapeutics Co Business Description

Other Exchanges JWCTF:USAJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
45GF Score

Get the complete analysis for HKSE:02126

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.61
Price
HK$4.08
GF Value